Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
5.05
-0.13 (-2.51%)
At close: Feb 27, 2026, 4:00 PM EST
5.10
+0.05 (0.99%)
After-hours: Feb 27, 2026, 7:14 PM EST
Niagen Bioscience Employees
Niagen Bioscience had 104 employees as of December 31, 2024. The number of employees decreased by 2 or -1.89% compared to the previous year.
Employees
104
Change (1Y)
-2
Growth (1Y)
-1.89%
Revenue / Employee
$1,199,125
Profits / Employee
$196,433
Market Cap
404.45M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 305 |
| Absci | 157 |
| Century Therapeutics | 150 |
| Enanta Pharmaceuticals | 120 |
| Armata Pharmaceuticals | 60 |
| PureTech Health | 56 |
| Anavex Life Sciences | 34 |
| Immix Biopharma | 21 |
NAGE News
- 2 days ago - Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction - Business Wire
- 3 days ago - Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen® - Business Wire
- 19 days ago - Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen - Business Wire
- 22 days ago - Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 - Business Wire
- 6 weeks ago - Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.* - Business Wire
- 2 months ago - Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast - Business Wire
- 3 months ago - Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years - Seeking Alpha
- 3 months ago - Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside) - Business Wire